Empowered Patient Podcast

Dr. Adam Kaplin is the Chief Scientific Officer of MyMD Pharmaceuticals which is developing a drug that gets to the cause of inflammation. Since chronic inflammation is a factor in pathological aging, managing inflammation shows opportunities for slowing aging. Their lead drug MyMD-1 is a TNF-a inhibitor that can cross the blood-brain barrier and treat the brain where other anti-TNF-a treatments do not.    Adam explains, "By delaying aging, what I mean is they not only lived longer, but they didn't lose their function. So, they retained their strength and their cognition. Because if we were only developing a drug that would just allow us all to get older and demented, that wouldn't be good for the economy, good for our personal health, good for anybody. So really, what we're excited about is the prospect of actually slowing the aging process and extending the healthy portion of our lifespans." "So, aging probably is going to end up being the result of two primary processes. One is inflammation, and that is th